Argos Aims To Automate Cell-Based Cancer Therapy
This article was originally published in Start Up
Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.
You may also be interested in...
With pivotal data expected in 2017 in metastatic kidney cancer, Argos hopes its drug will bridge the hot points of immuno-oncology and personalized medicine with a drug that extract’s RNA from a patient’s tumor and primes the dendritic cells to teach the immune system how to kill the cancer.
Unum Therapeutics Inc. is developing a new way of treating cancer that combines components of two different immune-system cells, natural killer cells and T cells. The start-up's therapeutic approach calls for modifying patients' own T cells with a hybrid molecule, called an antibody-coupled T-cell receptor , then co-administering them with antibodies designed to recognize specific proteins on the surface of tumors.
Cancer immunotherapy's potential payoff is big enough that acknowledged competitors are settling disputes, potential competitors are forging alliances, and start-ups like their chances of success. Profiles of Annias Immunotherapeutics, Costanoan Immunotherapies, and Unum Therapeutics.